Substance use and nicotine dependence in persistent, remittent, and late-onset ADHD: A 10-year longitudinal study from childhood to young adulthood by Ilbegi, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/199340
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
RESEARCH Open Access
Substance use and nicotine dependence in
persistent, remittent, and late-onset ADHD:
a 10-year longitudinal study from childhood
to young adulthood
Shahrzad Ilbegi1,9* , Annabeth P. Groenman2, Arnt Schellekens3,4, Catharina A. Hartman5, Pieter J. Hoekstra2,
Barbara Franke3,6, Stephen V. Faraone7, Nanda N. J. Rommelse3,8 and Jan K. Buitelaar1,8
Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is associated with substance use disorders (SUD;
alcohol and/or drug dependence) and nicotine dependence. This study aims to advance our knowledge about the
association between SUD, nicotine dependence, and the course of ADHD (persistent versus remittent ADHD and late-
onset ADHD).
Methods: ADHD, SUD, and nicotine dependence were longitudinally assessed (mean age at study entry 11.3 years,
mean age at follow-up 21.1 years) using structured psychiatric interviews and multi-informant questionnaires in a
subsample of the Dutch part of the International Multicenter ADHD Genetics study. Individuals with persistent ADHD
(n = 62), remittent ADHD (n = 12), late-onset ADHD (n = 18; age of onset after 12 years), unaffected siblings (n = 50), and
healthy controls (n = 47) were assessed. Hazard ratios (HR) with 95% confidence intervals (CIs) were estimated by Cox
regression and adjusted for clustered family data, gender, follow-up length, and current age.
Results: Individuals with persistent ADHD were at significantly higher risk of development of SUD relative to healthy
controls (HR = 4.56, CI 1.17–17.81). In contrast, levels of SUD in those with remittent ADHD were not different from
healthy controls (HR = 1.00, CI .07–13.02). ADHD persisters had also higher prevalence rates of nicotine dependence
(24.2%) than ADHD remitters (16.7%) and healthy controls (4.3%). A similar pattern was found in initially unaffected
siblings who met ADHD criteria at follow-up (“late-onset” ADHD); they had also a higher prevalence of SUD (33%)
compared to stable unaffected siblings (20%) and were at significantly increased risk of development of nicotine
dependence compared to healthy controls (HR = 13.04, CI 2.08–81.83).
Conclusions: SUD and nicotine dependence are associated with a negative ADHD outcome. Results further emphasize
the need for clinicians to comprehensively assess substance use when diagnosing ADHD in adolescents and adults.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder with onset in childhood; the
disorder is characterized by a heterogeneous etiology and
developmental course. Although severity of symptoms, es-
pecially of hyperactivity-impulsivity, often diminishes over
time, prospective longitudinal studies have shown that the
impairing symptoms of the disorder persist into adulthood
in approximately two thirds of children with ADHD, with
associated impairment across multiple domains [1]. Re-
cent studies have challenged the established notion of
ADHD as an exclusive childhood-onset disorder (onset
prior to 12 years of age) and reported onset of ADHD in
adolescence [2] and adulthood [3–5].
Various risk factors have been associated with a more
persistent course, such as higher ADHD symptom sever-
ity, presence of comorbidity (in particular conduct and
mood disorders), family history of ADHD, and psycho-
social and environmental adversities [6]. Longitudinal
studies of children with ADHD have consistently identi-
fied early substance use in adolescence as an important
negative outcome of the disorder [7–9]. Although many
studies have examined the link between ADHD and the
onset of substance use disorders (SUD; alcohol and/or
drug use disorder) and nicotine dependence (ND) [10,
11], few have investigated the association between SUD/
ND and the course of ADHD over time. While comor-
bid conduct disorder and oppositional defiant disorder
among children with ADHD increase the risk for SUD
[12], several studies have shown that ADHD is an inde-
pendent risk factor for the development of SUD in ado-
lescence and adulthood [10, 11]. Moreover, ND may
increase the risk of other SUD [13]. For example, in a
longitudinal study, Biederman et al. [14] found that
ADHD youth who smoked cigarettes were more likely to
subsequently use other substances and to develop SUD,
compared to other ADHD youth. This risk is further in-
creased when ADHD symptoms persist into adulthood,
with higher prevalence rates of SUD found among indi-
viduals with persistent than among those with remitted
ADHD [10, 15].
It is unclear whether there is also a link between
late-onset ADHD, referring to the onset of ADHD after
12 years of age, and SUD/ND. Several birth cohort stud-
ies have reported a 2.5–10.7% prevalence of a form of
ADHD that first emerged in mid/late adolescence or
(young) adulthood, so-called late-onset ADHD [3–5].
ADHD with onset after age 12 had patterns of psychi-
atric comorbidity, functional impairment, familial trans-
mission, and intelligence similar to childhood-onset
ADHD [2]. Careful assessment of ADHD symptoms that
emerged after childhood is crucial, since false positive
cases of adult-onset ADHD are common [16]. Moreover,
the reliability of an age at onset assessment could be
increased by using multiple informants or by selecting
(young) adult participants from prospective follow-up
studies.
The present study examined whether the course of
ADHD is associated with increased risks for developing
SUD (alcohol and/or drug use disorder) and ND from
childhood through young adulthood. We report findings
from a 10-year prospective, longitudinal study of a sub-
sample of the Dutch International Multicenter ADHD
Genetics (IMAGE) study cohort, including individuals
with persistent ADHD (n = 62), remittent ADHD (n =
12), late-onset ADHD (n = 18), unaffected siblings (n =
50), and healthy controls (n = 47). Given the extant lit-
erature that ADHD is a risk factor for SUD, we hypothe-
sized that the persistent ADHD group would show
higher rates of SUD and ND compared to the remittent
ADHD group, while we expected higher prevalence rates
of SUD and ND in the late-onset ADHD group com-
pared to the stable unaffected groups (unaffected sib-
lings and healthy controls). By including a high-risk
group of full biological siblings of ADHD probands, this
study allowed us to investigate the ADHD course and
development of SUD and ND over time in this group,
characterized by increased genetic and/or environmental
risk for ADHD.
Methods
Participants
All participants (n = 189) were a subsample of the Dutch
node of the IMAGE study, with initial assessment taking
place between 2003 and 2006 (wave 1) in VU University
Amsterdam and Radboud University Medical Center
Nijmegen. The IMAGE study recruited families with at
least one child with clinically diagnosed ADHD com-
bined type and their siblings regardless of ADHD diag-
nosis. Family members were of European Caucasian
descent. Inclusion criteria applying to both probands
and siblings included IQ≥ 70, no diagnosis of autism,
epilepsy, general learning difficulties, brain disorders,
and known genetic disorders. Additional healthy control
participants were recruited from primary and high
schools from the same geographical regions as the par-
ticipating ADHD probands and siblings. To assess SUD,
all families were re-invited for an intermediate follow-up
study (wave 2) and follow-up assessment 2 (wave 3) and
5 years later (wave 4; only the Nijmegen sub-cohort).
The present study included all children and adolescents
who participated in wave 1, 2, and 4 (in total N =
189). For the current analysis, wave 3 was left out
considering no information about SUD/ND was col-
lected. Note that affected siblings were grouped in
the ADHD affected group. Results for ADHD vs. un-
affected siblings vs. healthy controls based on the
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diagnosis at baseline are presented in Additional file 1:
Tables S1, S2, and Figure S1.
Measures
Diagnostic assessment
To determine ADHD diagnosis at wave 1 and wave 4, all
participants in the study were assessed similarly, using the
standard procedures of the IMAGE project, described
fully elsewhere [17]. The long version of Conners’ Parent
(CPRS-R:L) and Teacher Rating Scales (CTRS-R:L; [18])
were used to identify and quantify ADHD symptoms;
T-scores ≥ 63 on the Conners’ ADHD subscales inatten-
tion (L), hyperactivity/impulsivity (M), and total symp-
toms (N) and scores ≥ 90th percentile on the Strengths
and Difficulties Questionnaire (SDQ; [19]). Hyperactivity
subscale were considered clinical. At wave 4, the Adult
ADHD Rating Scales-Self-Report: Long Version (CAARS-
S:L) was added for participants ≥ 18 years. Participants
scoring clinically on any of these subscales were adminis-
tered a diagnostic interview. The diagnostic interview
changed from the Parental Account of Children’s Symp-
toms (PACS; [20]) at wave 1 to the Schedule for Affective
Disorders and Schizophrenia for School-Age Children
(K-SADS; [21]) at wave 4, both semi-structured, standard-
ized, investigator-based interviews with the parents as in-
formants. When children were 12 years or older, the
K-SADS was also administered individually (wave 4). Par-
ticipants with elevated scores on any of the screen items
were administered the full ADHD interview. A diagnostic
algorithm was used to establish ADHD status as defined
by Diagnostic and Statistical Manual of Mental Disorders:
(4th ed.; DSM-IV; [22]) and DSM-5 (5th ed.; [23]). ADHD
types (combined, predominantly inattentive, or predomin-
antly hyperactive/impulsive type) were established follow-
ing DSM-IV (wave 1) and DSM-5 (wave 4) criteria.
Comorbidities were assessed using the PACS at baseline
and using the K-SADS at follow-up. Classifications in both
interviews were established according to DSM-IV (wave
1) or DSM-5 (wave 4) criteria for comorbid conduct dis-
order and oppositional defiant disorder. Classifications of
DSM-IV anxiety, mood, and tic disorders were established
in the K-SADS at follow-up. Persistence of ADHD was de-
fined as meeting full DSM-IV criteria of ADHD/C at base-
line and meeting full DSM-5 criteria of ADHD regardless
of presentation at follow-up. Remission of ADHD was de-
fined as meeting full criteria of ADHD/C at baseline and
not meeting criteria of ADHD, any type, at follow-up.
Late-onset ADHD was defined as meeting full DSM-5 cri-
teria for ADHD at follow-up, with onset after 12 but prior
to 18 years of age, and not meeting criteria of ADHD, any
type, at baseline. Unaffected siblings and healthy controls
were defined as not meeting criteria of (subthreshold)
ADHD, any type, at baseline and follow-up. Subthreshold
ADHD cases were excluded from analyses. For both the
PACS and K-SADS, interviewers underwent compre-
hensive training by a team under the supervision of
E. Taylor at the London Institute of Psychiatry
(PACS) or J. Buitelaar at the Donders Institute for
Brain, Cognition and Behaviour, Radboud University
Medical Center, Nijmegen (K-SADS). The interviewers
were trained child psychiatrists, child psychologists,
or clinically trained researchers.
Substance use disorder assessment
For SUD assessment, a number of questionnaires were
completed by participants at wave 2 and wave 4. The
Drug Abuse Screening Test-20 [24] was used to assess
drug use disorders. Scores on this questionnaire may
range from 0 to 20. A cutoff of 5 was used to identify
possible drug use disorders [24]. The Fagerström Test
for Nicotine Dependence [25] was used to assess ND.
Scores on this questionnaire may vary between 0 and 10.
A cutoff of 2 was used to identify ND. Age of first nico-
tine use was also assessed in this questionnaire. The
Short Michigan Alcohol Screening Test [26] was admin-
istered to identify possible alcohol use disorders. Scores
varied between 0 and 13, and a cutoff of 4 was used to
define alcohol dependence. At wave 2, participants were
provided with a personal return envelope to increase
trust and to ensure confidentiality of sensitive informa-
tion. A best-estimate diagnosis of SUD was considered
present if either alcohol or drug use disorder according
to the DSM-IV criteria was present.
Anxiety and emotional lability
T-scores on the CPRS-R:L subscales anxious/shy (D)
and emotional lability (J) were used to assess levels of
anxiety and emotional lability.
Procedure
At baseline, families were recruited from clinics and via
advertisements. Testing took place at the Donders Insti-
tute and Radboudumc in Nijmegen. All ratings of behav-
ioral functioning pertained the participant’s functioning
off medication. Families were financially compensated
for participating in the study.
Statistical analysis
All analyses were conducted using SPSS version 24.0
(IBM SPSS Statistics for Macintosh, Version 24.0). Par-
ticipants were divided into five groups based on pro-
spective reports of ADHD symptoms (persistent,
remittent and late-onset ADHD, (stable) unaffected sib-
lings, and healthy controls). Analyses of variance were
performed to assess whether groups (persistent vs. re-
mittent and late-onset ADHD vs. unaffected siblings)
differed on IQ at baseline, age at follow-up, follow-up
interval, emotional lability, and anxiety T-scores of the
Ilbegi et al. Journal of Neurodevelopmental Disorders           (2018) 10:42 Page 3 of 8
CPRS-R:L and T-scores on the ADHD scales of the
CPRS-R:L. A chi-square test assessed whether groups
differed in the proportion of males. Any variables show-
ing significant differences between groups were included
as covariates. Group differences in risk of developing
SUDs and ND were assessed using Cox proportional
hazard models. Correction for clustered (family) data
was performed using robust standard errors [27]. The
model used the age of first substance or nicotine use as
the survival time for the cases (i.e., those with either
SUDs or ND) and current age was used as the time of
censoring for the non-cases. The event is defined as life-
time SUD or ND. The effect of stimulant medication use
(yes/no) on the development of SUDs or ND was
assessed by using this variable as a group in Cox regres-
sion using SUDs or ND as outcome variables. Finally, we
checked whether the associations between ND and SUD
and course of ADHD were not driven by group differ-
ences in levels of anxiety and emotional lability.
Results
Attrition analyses
Selective attrition was investigated by comparing partici-
pants successfully followed up (n = 189) with participants
lost to follow up on variables reported in this study
available at baseline. No significant group differences
were found (.14 < p < .99).
Demographic and clinical characteristics
Additional file 1: Table S3 describes the demographic and
clinical characteristics of the five groups. Of 74 children
with ADHD combined type at baseline, 62/74 (84%) per-
sisted in a full ADHD diagnosis (50% ADHD inattentive-
type, 9.7% ADHD hyperactive/impulsive-type, 40.3%
ADHD combined type) and 12/74 (16%) remitted from
the disorder at follow-up. Of note, 18/68 (26%) of the un-
affected siblings at baseline met diagnostic criteria of
ADHD at follow-up (14 adolescent-onset and 4 adult-
onset), while no late-onset (adolescent nor adult-onset)
ADHD was found in healthy controls (n = 47). There were
small but statistically significant group differences in
current age, follow-up interval, gender, and IQ. All subse-
quent analyses were statistically corrected for current age,
follow-up interval, and gender.
No significant differences in anxiety and emotional la-
bility scores were found between siblings with late-onset
ADHD and (stable) unaffected siblings at baseline (see
Additional file 1: Table S1 for details). Between baseline
and follow-up, individuals with persistent and remittent
ADHD, (stable) unaffected siblings, and healthy controls
showed a decrease in anxiety and emotional lability
symptom severity scores, while the late-onset ADHD
group remained stable in their levels of anxiety and
emotional lability. Levels of emotional lability in the
late-onset ADHD group were higher than in (stable)
unaffected siblings and similar to the persistent
ADHD group at follow-up, but not in the clinical
range. It is therefore unlikely that this explains clin-
ical levels of ADHD symptoms in young adulthood
(see Additional file 1: Table S3 for details).
Risk for substance use disorder and nicotine dependence
in persisters and remitters
A main group effect was found when comparing persisters
with remitters and healthy controls (Wald F = 4.25, p
= .018). Individuals with persistent ADHD were 4.6 times
(95% CI 1.17–17.81) more likely to develop a SUD com-
pared to healthy controls, whereas remitters did not differ
in risk compared to healthy controls (HR = 1.0, 95% CI
.07–13.02). There was no significant difference in risk of
developing a SUD between persisters and remitters, al-
though the small sample size and wide confidence interval
likely contributed to this (HR = .22, 95% CI .03–13.02). No
main effect of group was found when persisters, remitters,
and healthy controls were compared on their risk of devel-
oping nicotine dependence (Wald F = 1.48, p = .23), al-
though, again, the overall pattern of findings suggests that
persisters and remitters had higher nicotine dependence
than healthy controls; see Table 1 and Fig. 1a.
Risk for substance use disorder and nicotine dependence
in late-onset ADHD and stable unaffected siblings
No significant difference between late-onset ADHD, un-
affected siblings, and healthy controls was found when
comparing them on the risk of developing a SUD (Wald
F = 2.28, p = .11). Again, the pattern of findings suggests
that late-onset ADHD had higher SUD levels (see Fig. 1).
However, a main effect of group was found when look-
ing at nicotine dependence (Wald F = 4.40, p = .016).
Those with late-onset ADHD were at increased risk of
developing nicotine dependence compared to healthy
controls (HR = 13.04, 95% CI 2.08–81.83), but not com-
pared to unaffected siblings (HR = .57, 95% CI .21–1.6).
Unaffected siblings and healthy controls did not signifi-
cantly differ in their risk of developing nicotine depend-
ence, although the small sample size and wide
confidence interval likely contributed to this, with the
pattern of findings suggesting increased prevalence of
nicotine dependence in unaffected siblings compared to
healthy controls (HR = 7.47, 95% CI .91–61.13; also see
Table 2 and Fig. 1b).
Medication use
No significant effect of stimulant medication use was
found on the development of SUDs (Wald F = .72,
p = .40) or nicotine dependence (Wald F = .47 p = .49).
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Discussion
To our knowledge, this study provides the first data on
the association between SUD/ND and the course of
ADHD among probands with ADHD and their bio-
logical siblings in a 10-year prospective longitudinal
study. Results showed that ADHD persisters were at sig-
nificantly higher risk for the subsequent development of
SUD relative to healthy controls, in contrast to a similar
level of SUD in ADHD remitters vs healthy controls.
ADHD persisters had also higher (albeit non-significant)
prevalence rates of ND than ADHD remitters and
healthy controls. A similar pattern of results was found
for those with late-onset ADHD who had a higher
prevalence of SUD compared to healthy controls, while
no higher prevalence rates of SUD were found in stable
unaffected siblings compared to healthy controls. Further,
those with late-onset ADHD were at significantly higher
risk for the subsequent development of ND compared to
healthy controls, in contrast to a similar level of SUD
in stable unaffected siblings versus healthy controls.
Although not all results reached statistical significance,
the pattern of findings suggests SUD and ND are associ-
ated with a negative ADHD outcome (i.e., persistent
ADHD and/or late-onset ADHD) and further emphasize
the need for clinicians to make a comprehensive assess-
ment of substance use when diagnosing ADHD.
Table 1 Prevalence rates of SUD and ND in ADHD persisters, remitters, and healthy controls
Prevalence rates Hazard ratios
Persisters
n = 62
Remitters
n = 12
HC
n = 47
Persisters
vs.
HC
Persisters
vs.
Remitters
Remitters
vs.
HC
n % n % n % HR 95% CI HR 95% CI HR 95% CI
Substance use disorder 22 35.5 1 8.3 6 12.8 4.56* 1.17–17.81 .22 .03–1.57 1.00 .07–13.02
Nicotine dependence 15 24.2 2 16.7 2 4.3 4.38 .77–25.02 .66 .13–3.41 2.90 .29–29.57
SUD substance use disorder, ND nicotine dependence, ADHD attention deficit hyperactivity disorder, HC healthy controls. Hazard ratios (HR) were calculated using
Cox proportional hazard regression. All comparisons were corrected for gender and follow-up interval in years. 95% CI 95% confidence interval. *Significant
at p < 0.05
A
B
Fig. 1 Cumulative lifetime risk for any substance use disorder and nicotine dependence in a persisters, remitters and healthy controls and b late-
onset ADHD, unaffected siblings and healthy controls
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Previous research has suggested that the persistence of
ADHD is a risk factor for the development of SUD [15].
Our study replicated that finding and extended the ana-
lysis by showing the same pattern of results in biological
siblings with late-onset ADHD. The findings suggest that
late-onset ADHD is also associated with ND. ND is
often described as a gateway drug to illicit drug use [28],
and studies consistently identify the increased risk of
ND in individuals with ADHD [13]. In our samples, both
persistent and remitted ADHD had higher rates of ND
than the controls, although the effects were not signifi-
cant. This is likely due to small sample sizes and hence
limited statistical power. Given that SUD and ND might
be associated with adverse outcome of ADHD, identifi-
cation of early risk factors and preventive interventions
in children at risk for a persistent course of ADHD as
well as their biological siblings might be crucial.
Disentangling the nature of the association between
ADHD and SUD/ND remains challenging. Although the
literature is consistent in showing that the onset of
ADHD precedes the development of SUD, high levels of
substance use in adolescence may adversely affect
still-maturing prefrontal brain regions leading to behav-
ior regulation deficits associated with ADHD [29]. In
this perspective, substance use could negatively influence
the course of ADHD in addition to the widely accepted
ADHD-to-substance use pathway. Alternatively, because
SUD often manifests in adolescence and young adult-
hood, the SUDs itself might elicit symptoms of ADHD
and be mistakenly identified as “late-onset of ADHD”
[30]. A third possible explanation for the association be-
tween ADHD course and SUD/ND is that the relation
between ADHD and SUD/ND is largely explained by a
common third factor that increases both the risk for a
detrimental ADHD course as well as increase the risk
for SUD/ND, for instance, environmental factors and/or
shared genetic lability to both disorders [31, 32].
Our findings offer some support for the possibility of
late-onset ADHD, a proportion of biological siblings un-
affected at baseline met DSM-5 criteria of ADHD in
young adulthood, with age of onset after 12 but prior to
18 years of age. Since all participants were comprehen-
sively assessed on ADHD and comorbid disorders by
multi-informant questionnaires and interviews in child-
hood, as well as in (young) adulthood, it is unlikely that
these cases represented individuals with undetected
childhood symptoms (i.e., late-identified rather than
late-onset) [33–35] or false positive cases of late-onset
ADHD. Although emotional lability scores at follow-up
were higher in the late-onset ADHD group compared to
the stable unaffected siblings group, these levels were
not in the clinical range. An explanation for late-onset
ADHD in biological siblings might be that unaffected
siblings carry vulnerable heritable traits for ADHD and
often already have increased levels of ADHD symptoms
in childhood. However, their ADHD symptoms might
not be severe enough to merit a clinical diagnosis. Clin-
ical levels of ADHD might manifest later in life, when
the demands of life increase or until they can no longer
rely on or compensate by protective factors, such as high
cognitive ability [4]. Future studies should investigate
mechanisms associated with later onset ADHD in ado-
lescence or adulthood, e.g., neuropsychological profile
that possibly could differentiate individuals developing
late-onset ADHD versus stable unaffected individuals.
Previous family studies of ADHD have shown that
ADHD and SUD co-aggregate in families [30, 36]. In ac-
cordance with these findings, we found an increased risk
of SUD among unaffected siblings of ADHD probands.
Importantly, these findings indicate that there is no dir-
ect relationship between ADHD and SUD and that
shared genetic lability and/or family environment risk
factors to both disorders might contribute to the devel-
opment of both. Previous findings from our study
showed no increased risk of SUD in unaffected bio-
logical siblings of ADHD probands [11]; however, our
participants in this study were still relatively young
(mean 17 years) and might not have completely traversed
the developmental pathway to substance use and ND.
The present finding supports the notion that SUD in-
creases during the late adolescent and young adult years.
Taken together, our findings support the hypothesis that
Table 2 Prevalence rates of SUD and ND in late-onset ADHD, (stable) unaffected siblings, and healthy controls
Prevalence rates Hazard ratios
LO-ADHD
n = 18
US
n = 50
HC
n = 47
LO-ADHD
vs.
HC
LO-ADHD
vs.
US
US
vs.
HC
n % n % n % HR 95% CI HR 95% CI HR 95% CI
Substance use disorder 6 33.3 10 20.0 6 12.8 5.15 1.04–25.66 .41 .14–1.23 2.11 .51–8.73
Nicotine dependence 5 27.8 8 16.0 2 4.3 13.04* 2.08–81.83 .57 .21–1.60 7.47 .91–61.13
SUD substance use disorder, ND nicotine dependence, LO-ADHD late-onset attention deficit hyperactivity disorder, US unaffected siblings, HC healthy controls.
Hazard ratios (HR) were calculated using Cox proportional hazard regression. All comparisons were corrected for gender and follow-up interval in years. 95% CI
95% confidence interval. *Significant at p < 0.05
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ADHD is a familial risk factor for SUD and that bio-
logical siblings represent a group who are at high risk
for the subsequent development of both SUD and
late-onset ADHD.
Some methodological limitations should be taken into
account in the interpretation of the results. Given that
several of the subgroup samples were relatively small,
detecting significant group differences was more diffi-
cult. However, our results were in the expected direc-
tion, indicating that significant results are expected with
a larger sample. Furthermore, SUD and ND were
assessed by self-reports. We used adult cutoff scores for
the self-report questionnaires, while not all subjects
reached adulthood at the time of assessment. Although
this approach would not have biased results to finding
spurious case-control differences, it may have influenced
our estimates of prevalence.
Conclusions
This study contributes to the understanding of the associ-
ation between substance use and the course of ADHD
over time. In particular, children with persistent ADHD
have higher risks of developing alcohol and/or drug de-
pendence over time compared to healthy controls, while
this was not found for individuals with remittent ADHD.
The same pattern of findings was found for siblings devel-
oping late-onset ADHD versus those who remained un-
affected. This suggests that SUD and ND seem to be
associated with a negative ADHD outcome. Although the
mechanisms governing these associations are not yet fully
understood, the findings from this study underscore the
clinical and public health significance of SUD in the course
of ADHD. This study emphasizes the importance of pre-
ventive interventions in biological siblings, considering
their increased risks of developing both SUD and ADHD.
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